ACM
NTLA icon

Atika Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Atika Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-850
Closed -$10.1M – 96
2021
Q4 		$10.1M Buy
+850
New +$106K 0.71% 54

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Atika Capital Management's NTLA Position: Q4 2024 in Review

Atika Capital Management sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 92,000 shares — an estimated $1.89M sold.

Atika Capital Management first reported a position in NTLA in Q2 2021 and held it in 6 quarters. The position peaked at $10.2M in Q2 2021. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • Atika Capital Management reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Atika Capital Management sold 92,000 Intellia Therapeutics shares in Q4 2024, an estimated $1.89M.
  • Atika Capital Management first reported a position in Intellia Therapeutics in Q2 2021 and held it in 6 quarters.
  • Atika Capital Management's Intellia Therapeutics position peaked at $10.2M in Q2 2021.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Atika Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.